CA4 and thyroid gland carcinoma: To improve the low water solubility of CA-4, researchers developed CA-4, and optimized this pharmacokinetic challenge by innovating CA-4P (fosbretabulin) (Figure 1), which was applied for thyroid cancer, and was approved by the FDA in 2018 [17,30].